Pericapsular Nerve Group With Lateral Femoral Cutaneous Nerve Block vs Suprainguinal Fascia Iliaca Block for Analgesia in Total Hip Arthroplasty: A Prospective Comparative Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-01

Study Completion Date

2024-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective observational cohort comparing analgesic efficacy of suprainguinal fascia iliaca block (SFIB) vs pericapsular nerve group block combined with lateral femoral cutaneous nerve block (PENG+LFCN) in primary total hip arthroplasty under general anesthesia (n=48). Outcomes include VAS pain at rest and with movement at 3, 12, 24, 48 h; morphine use (0-3, 3-12, 12-24, 24-48 h; total 0-48 h); quadriceps strength at 6 and 24 h; physiotherapy participation at 24 and 48 h; and adverse events within 48 h.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Pain Relief After Hip Fracture Surgery: Hip and Groin Nerve Block

NCT06443892

Opioid Use Pain, Postoperative Hip Fractures

COMPLETED

Comparison of the Analgesic Effectiveness of Pericapsular Nerve Block and Suprainguinal Fascia Iliac Block Application

NCT06672289

Hip Surgery

NOT_YET_RECRUITING

The Analgesic Effect of Pericapsular Nerve Group Block With Lateral Femoral Cutaneous Nerve Block and Pericapsular Nerve Group Block With Supra-inguinal Fascia Iliaca Block in Hip Hemiarthroplasty

NCT06577103

Pericapsular Nerve Group Block Lateral Femoral Cutaneous Nerve Block Supra-inguinal Fascia Iliaca Block +1 more

COMPLETED NA

Comparison of Continuous Fascia Iliaca Compartment Block With Continuous PENG Block in Total Hip Replacement Cases

NCT06806865

Postoperative Pain Regional Anesthesia Pain Management +1 more

COMPLETED NA

PENG and LFCN Block Versus FIC Block for Multimodal Analgesia After Total Hip Replacement Surgery: a Retrospective Analysis Focused on Movement (Retro-PvF)

NCT06342102

Regional Anesthesia Block Regional Anesthesia Total Hip Replacement Surgery +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Adults undergoing primary posterolateral THA under general anesthesia were included if they received either SFIB or PENG+LFCN. Pain (VAS at rest and with 45° passive flexion) was recorded at 3, 12, 24, and 48 h. Morphine via PCA was recorded for 0-3, 3-12, 12-24, and 24-48 h, with a 0-48 h total. Quadriceps strength (0-2 scale) was assessed at 6 and 24 h; physiotherapy participation at 24 and 48 h; opioid- or block-related adverse events through 48 h.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coxarthrosis; Primary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SFIB

Patients undergoing THA who received ultrasound-guided SFIB with 0.25% bupivacaine 40 mL under the fascia iliaca with cranial spread.

No interventions assigned to this group

PENG

Patients undergoing THA who received ultrasound-guided PENG (0.5% bupivacaine 15 mL) at the iliopubic eminence plus LFCN block (0.5% bupivacaine 5 mL) distal to the inguinal ligament.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are scheduled to undergo primary total hip arthroplasty with a diagnosis of coxarthosis

Exclusion Criteria

* Patients who have a history of neuropathy, patients with renal and hepatic insufficiency, patients with known coagulopathy, patients with a history of allergy to local anesthetics, patients with a history of inguinal surgery on the same side and patients with impaired mental status

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No